Scroll Top

New in MPO: weight loss drugs and Medtech

In my latest column for MPO, I discuss the risks new weight-loss drugs (GLP1s) may pose to OEMs and contract manufacturers.

Heavy Harm or Slim Chance? The Impact of GLP1s on Medtech

The highest existential risk is not to OEMs but to contract manufacturers specializing in the areas where GLP1s will delay surgeries.

Read the column here.

Tony Freeman / About Author

Tony Freeman is the president of A.S. Freeman Advisors LLC, a merger and acquisitions advisory firm serving the precision manufacturing and specialty materials industries. Often referred to as “The Toast of Medtech,” Tony is known for his rapier analysis, crack marksmanship, and superb taste in western wear. He can be reached at tfreeman@asfreeman.com.

New in MPO: weight loss drugs and Medtech

Share this:

Related